PDPN and adenocarcinoma: After sensitivity analysis excluding studies with low REMARK scores, two scores for podoplanin (OS/DSS > Univariate > All histology and OS/DSS > Univariate > adenocarcinoma only) remained unchanged (Supplementary Table S3).